The chemist and druggist [electronic resource] . See over page for references and product information For more information, please References 1. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Lower Urinary Tract: Guideline for the primary caremanagement of male lower urinary tract symptoms. BJU International 2004; 93:985-990. 2. Department of Health. Prescription Cost Analysis Data. England 2004 p214 Date accessed4 September 2009. 3. Narayan P et al. Journal of Urology 1998,160:1701 -1706. 4. SPC for Flomax Relief MR. 5. Narayan P, Evans CP
The chemist and druggist [electronic resource] . See over page for references and product information For more information, please References 1. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Lower Urinary Tract: Guideline for the primary caremanagement of male lower urinary tract symptoms. BJU International 2004; 93:985-990. 2. Department of Health. Prescription Cost Analysis Data. England 2004 p214 Date accessed4 September 2009. 3. Narayan P et al. Journal of Urology 1998,160:1701 -1706. 4. SPC for Flomax Relief MR. 5. Narayan P, Evans CP Moon T. Long term safety and efficacy of tamsulosin for the treatment of lowerurinary tract symptoms associated with benign prostatic of Urology 2003; 170:498-502. 6. Schulman CC, LockTMTW, Buzelein J-M, Boeminghaus F, Stephenson TP Talja M and the members of theEuropean Tamsulosin Study Group. Long-term use ofTamsulosin to treat lower urinary tract symptoms/be-nign prostatic hyperplasia. Journal of Urology 2001; 166:1358- 1363. 7. Lowe F, Narayan R Djavan B. Prospective, randomised, multicenter trial to evaluate the rapidity of onsetand
Size: 1795px × 1393px
Photo credit: © The Reading Room / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: ., bookcentury1800, bookdecade185, booksubjectpharmacy, bookyear1859
